NCT00627068

Completed

The Role of Nitric Oxide Synthase in Circulating Progenitor ...

University of California, San Francisco Source

Compare

Other study identifiers

Sponsor study identifier

HL086917

Study Type

observational

Actual enrollment (reported)

60

Locations

1 country

Sites

1

Timeline

Study Start

July 2007

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2010

Actual (reported)

Study Completion

December 2010

Actual (reported)

Brief Summary

Our main hypothesis is that EPC function is impaired in some populations with high cardiovascular risk as a result of reduced eNOS-dependent NO production.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 60 participants
Study completion date: December 2010
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
July 2007
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
February 21, 2008
Actual (reported)
First Posted
February 29, 2008
Actual (reported)
Primary Completion
December 2010
Actual (reported)
Study Completion
December 2010
Actual (reported)

Last Updated: September 20, 2011
Status Verified: September 2011
Last Update Submitted: September 16, 2011

Conditions

Cardiovascular Disease

Keywords

cardiovascularvasodilationendotheliumSubjects with high cardiovascular risk

Study Arms (4)

1

High cardiovascular risk age over 61 years.

2

Low Cardiovascular risk age over 61.

3

High cardiovascular risk age over 25 but under 61.

4

Low cardiovascular risk age over 25 under 61.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Population in both low and high risk groups should represent the general population.

You may qualify if:

Willing and able to give written informed consent and comply with study requirements

Sponsors & Collaborators

University of California, San Francisco
Otherlead

Study Sites (1)

UCSF, Department of Cardiology

San Francisco, California, 94143, United States

Biospecimen

Retention: SAMPLES WITHOUT DNA

whole blood

MeSH Terms

Conditions

Cardiovascular DiseasesAneurysm

Condition Hierarchy (Ancestors)

Vascular Diseases

Study Officials

Yerem Yeghiazarians, M.D
University of California, San Francisco
PRINCIPAL INVESTIGATOR

Enrollment

60 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Assistant Clinical Professor

Study Record Dates

First Submitted

February 21, 2008

First Posted

February 29, 2008

Study Start

July 2007

Date type not reported

This date has not been verified as actual or estimated.

NCT00938340

Postprandial Effects of Walnut Components Versus Whole Walnuts on Cardiovascular Disease (CVD) Risk Reduction

Not ApplicableCompleted

NCT00907465

Sedentary Behavior in African Americans

Completed

NCT00829491

Denver Health Cardiovascular Disease (CVD) Prevention Program

Not ApplicableCompleted

NCT00551746

The Purple Grape Juice Study

Not ApplicableCompleted

NCT00508638

Identifying High- and Low-Risk Heart Failure Patients in the Emergency Department (The Stratify Study)

Completed

NCT00458874

Better Adherence to Therapeutic Lifestyle Change Efforts Trial

Not ApplicableCompleted

Adult of 18 years or older

Subjects willing to provide blood and tissue samples

You may not qualify if:

Failure to give informed consent.
Those unable to consent for themselves.
Those who cannot read English.
Patients on Viagra, Levitra, or Cialis
Patients with malignant disease
Patients with hematological abnormalities
Patients with fevers of unknown origin
Severe comorbidity or alcohol/drug dependence
Women who are post-menopausal and on hormone replacement therapy, or premenopausal and on birth control pills (premenopausal women will be screened verbally and then by assay of LH and FSH levels in blood samples to identify women in the follicular phase of their menstrual cycle, to reduce variability)

Contact the study team to confirm eligibility.

Primary Completion

December 2010

Actual (reported)

Study Completion

December 2010

Actual (reported)

Last Updated

September 20, 2011

Record last verified: 2011-09

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00627068
Data provider: ClinicalTrials.gov
Source updated: 2011-09-20
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:22:32 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Study Arms (4)

1

2

3

4

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations